Hemocompatibility of Membranes for Double Filtration Lipoprotein Apheresis

Phase 4

• Conditions: severe lipid disorders; E78; Disorders of lipoprotein metabolism and other lipidaemias

• Registration Number: DRKS00014075
• Lead Sponsor: niversitätsklinik Würzburg, Nephrologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Age = 18 years; lipometabolic disorder requiring lipoprotein apheresis; routinely scheduled double filtration lipoprotein apheresis; Hematocrit = 37 %; stable anticoagulation regimen for apheresis; no ongoing infection; signed informed consent form

Exclusion Criteria

Inclusion criteria not met; known HIV or hepatitis B or C infection; pregnancy; unstable clinical condition (e.g. cardiac or vascular instability); known coagulation problems; patients participating in another study interfering with the planned trial

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
White blood cell counts and complement factor C5a plasma level at baseline and during the treatment after 5, 10, 15, 20, 25 und 30 min as well as at the end<br>

Secondary Outcome Measures

Name	Time	Method
Thrombin-antithrombin-III plasma level; platelet count, CD62L, and CD62P in blood at baseline and during the treatment after 30 min and at the end<br>